SEC Company Response from Forma Therapeutics Holdings, Inc. (CIK 0001538927) — Dec 8, 2020
Forma Therapeutics Holdings, Inc. (CIK 0001538927)
Date: Dec. 8, 2020 · CIK: 0001538927 · Accession: 0001193125-20-312885
AI Filing Summary & Sentiment
File numbers found in text: 333-251198
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Forma Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-251198
Dear Sir/Madam:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, wish to advise you that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of Preliminary Prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
In accordance with Rule 461 of the Act, we hereby join in the request of Forma Therapeutics Holdings, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 5:00 p.m. Eastern time on December 10, 2020, or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
Very truly yours,
By:
Show Raw Text
CORRESP 1 filename1.htm CORRESP Jefferies LLC 520 Madison Avenue New York, New York 10022 SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010-3629 December 8, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Forma Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-251198 Dear Sir/Madam: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, wish to advise you that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of Preliminary Prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. In accordance with Rule 461 of the Act, we hereby join in the request of Forma Therapeutics Holdings, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 5:00 p.m. Eastern time on December 10, 2020, or as soon thereafter as practicable. [Remainder of page intentionally left blank] Very truly yours, By: JEFFERIES LLC By: /s/ Dustin Tyner Name: Dustin Tyner Title: Managing Director By: SVB LEERINK LLC By: /s/ Irena Melnikova Name: Irena Melnikova Title: Managing Director By: CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Rebecca Kotkin Name: Rebecca Kotkin Title: Director [Signature page to Acceleration Request Letter]